Abstract

Background5-Fluorouracil (5-FU) is the cornerstone of chemotherapeutic treatment for patients with colorectal cancer. The enzyme thymidine phosphorylase (TP) catalyzes the conversion of 5-FU to its active metabolite, 5-fluoro-2’-deoxyuridine. TP is expressed in tumour epithelial cells and stromal cells, particularly in tumour-associated macrophages. These macrophages may affect sensitivity to chemotherapy. Previously, we identified TP as a predictive factor in microdissected tumour samples of patients with advanced colorectal cancer. In the present study, we analysed TP expression in tissues and associated stromal cells from patients with advanced colorectal cancer and associated TP levels to tumour response and time-to-event variables during first-line chemotherapy treatment. We also investigated the association between serum TP levels at the time of surgery and gene expression in primary tumour tissues.MethodsThis study included 125 patients with metastatic colorectal cancer treated with first-line 5-FU-based chemotherapy. To quantify TP gene expression levels in tumour tissues, real-time polymerase chain reaction was performed using the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). TP protein concentration in matched serum samples was determined using an enzyme-linked immunosorbent assay system (USCN Life Science Inc.).ResultsThe tumour response rate was 31%, and 30% of patients exhibited stable disease. No associations between TP expression level and age or gender were observed. Levels of TP mRNA in mucosa and tumours were positively correlated (r = 0.41, p < 0.01). No correlation between TP expression and tumour response rate was observed. Time to progression was significantly longer in patients with high TP expression (p < 0.01). Serum TP protein levels were not associated with tumour response or time-to-event variables and did not correlate with gene expression in tumour tissues.ConclusionsHigh TP gene expression in non-microdissected tumour tissues of patients with advanced colorectal cancer correlates with longer time to progression, which could be related to treatment. These results are in contrast to previous studies where microdissected tumour cells were analysed and may be due to the presence of adjacent stromal cells. Serum TP protein expression does not correlate to TP gene expression in tissues of patients with advanced colorectal cancer.

Highlights

  • To date, 5-fluorouracil (5-FU) constitutes the fundamental basis of chemotherapy treatment for patients with colorectal cancer

  • The expression of tumour TP (tTP) was associated with tumour location, with rectal carcinomas exhibiting higher median tTP expression compared with colon carcinomas (0.32, IQR 0.10–0.57 and 0.15, IQR 0.060–0.37, respectively, p < 0.01)

  • We observed a positive correlation between tTP and mucosa thymidine phosphorylase (TP)

Read more

Summary

Introduction

5-fluorouracil (5-FU) constitutes the fundamental basis of chemotherapy treatment for patients with colorectal cancer. Previous studies have shown that TP levels are higher in tumour compared with normal tissues in a wide range of solid tumours [2,3,4,5]. TP and its catalytic product, 2-deoxy-D-ribose-1-phosphate act as angiogenic factors via induction of endothelial cell migration and tube formation [6,7,8,9]. TP expression is observed in tumour epithelial cells and stromal cells, in tumour-associated macrophages (TAMs) [4,8,11]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call